Cassava Sciences’ year-to-date stock performance.
Cassava Sciences: “They do have an Alzheimer’s trial, but Lilly has an Alzheimer’s formulation that is very good. And Lilly does have the edge on everybody else.”
Mobileye Global’s year-to-date stock performance.
Mobileye Global: “…I think it’s just too hard to tell, I’m going to stay away from it.”
Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.
Questions for Cramer?
Call Cramer: 1-800-743-CNBC
Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money Twitter – Jim Cramer Twitter – Facebook – Instagram
Questions, comments, suggestions for the “Mad Money” website? [email protected]